The Fight Against Aging

Quincy Bioscience is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat the diseases of aging. The company's products focus on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions commonly thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Quincy Bioscience is set apart by its cutting-edge applications of the calcium-binding protein aequorin, which is breaking new ground in the fight against neuronal degeneration.


Quincy Bioscience is dedicated to fighting aging on several fronts. In addition to our pharmaceutical aspirations we have developed a novel dietary supplement using our patent-pending technology. Our first supplement, Prevagen™, is now available nationwide in health food stores and Rite-Aid chain drug stores. The only supplement from a jellyfish, Prevagen keeps brain cells alive longer. * Our research shows a 28-55% reduction in cellular death when treated with the jellyfish compound within Prevagen. Prevagen was developed by Quincy Bioscience and is the first supplement to address aging through the restoration of calcium-binding proteins. For more information please visit our website at www.prevagen.com.

Recent News about Quincy Bioscience

August 26, 2007: Talk 650 KSTE - Mark Underwood appears on The Wide World of Health

May 24, 2007: NBC - Jellyfish helping prevent injury from strokes

May 16, 2007: Milwaukee Journal Sentinel - Madison company to use animal's proteins to fight aging

May 1, 2007: Channel 3 WISC TV Madison - Jellyfish Fight Aging

March 23, 2007: Quincy Bioscience presents at BIO 2007 Convention in Boston, MS

 

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.

Patent Pending

Skip Navigation Links
Home
Prevagen.com
Prevagenpro.com
News Room
Contact Us
Links


Copyright © 2008 Quincy Bioscience All rights reserved |  Terms of Use


Having problems viewing the page? Click here.